12 results about "Diastolic heart failure" patented technology

The invention discloses a pyrimidinedione derivative as well as a preparation method and application thereof. Molecules of the pyrimidinedione derivative have better myosin inhibitory activity, also have antioxidant effects of DPPH and / or MDA and the like and anti-ferroptosis activity, and can be applied to treatment / prevention of heart myosin, anti-oxidative stress and anti-ferroptosis mechanism related diseases. The diseases or symptoms mainly comprise hypertrophic cardiomyopathy, diastolic heart failure, left ventricular hypertrophy, heart diseases with pathophysiological characteristics related to the hypertrophic cardiomyopathy, or other disease states and conditions which are obvious to those skilled in the art, or a prodrug thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt thereof. Or a hydrate or solvate thereof, and a pharmaceutical composition containing the same.

The present invention relates to a D-galactopyranose compound of formula (1)whereinthe pyranose ring is α-D-galactopyranose, and these compounds are high affinity galectin-1 and / or galectin 3 inhibitors for use in treatment of inflammation; fibrosis; scarring; keloid formation; aberrant scar formation; surgical adhesions; septic shock; cancer; metastasising cancers; autoimmune diseases, metabolic disorders; heart disease; heart failure; pathological angiogenesis; eye diseases; atherosclerosis; metabolic diseases; diabetes type I; diabetes type II; insulin resistance; Diastolic heart failure; asthma; liver disorders.

A method of reducing left atrial pressure is provided for treating diastolic heart failure. A puncture catheter is advanced into a coronary sinus for creating an opening in a wall between the coronary sinus and a left atrium of a heart. A cauterizing tool may be used to create a controlled scarring pattern in the tissue along the opening. After the opening is created, a blood flow path is provided from the left atrium to the coronary sinus for reducing blood pressure in the left atrium and thereby alleviating symptoms of heart failure. If necessary, a shunt device may be implanted within the opening to ensure that the blood flow path remains open.

This document relates to devices and methods for the treatment of heart conditions. For example, this document provides devices and methods for treating heart failure with preserved ejection fraction, including diastolic heart failure, by performing a pericardial modification procedure.

The system and method described provides for the non-invasive detection and quantification of systolic and diastolic heart failure, including subclinical, not-yet symptomatic systolic and diastolic heart failure. The instant invention is a new way to process and derive clinical meaning and prognoses from physiomic data. The invention is predicated upon extracting data that is shown graphically in the Wiggers Diagram which shows the entire cardiac cycle with simultaneous data streams, the ECG, phonocardiogram, and Left Ventricular Pressure.

A method for treating diastolic heart failure (heart failure with preserved ejection fraction (HFpEF)) in a subject in need thereof is provided including administering a therapeutically effective amount of a galectin-3 inhibitor to the subject.

The system and method described provides for the non-invasive detection and quantification of systolic and diastolic heart failure, including subclinical, not-yet symptomatic systolic and diastolic heart failure.

This document relates to devices and methods for the treatment of heart conditions. For example, this document provides devices and methods for treating heart failure with preserved ejection fraction, including diastolic heart failure, by performing a pericardial modification procedure.

The application discloses an early evaluation system for diastolic heart dysfunction, and relates to the technical field of medical treatment. IVR and SR E ; a storage module is used for storing the normal reference ranges of SR IVR and SR E of healthy people in different age groups; an evaluation output module is used for comparing the SR IVR and SRE of the examinee with the normal reference ranges in the storage module, and outputting the early evaluation result of the diastolic heart dysfunction; the secondary screening is conducted on the hypertensive patients who cannot be diagnosed as having the diastolic heart dysfunction through the conventional ultrasound, so that the basis for early intervention is provided, and the incidence of the diastolic heart failure can be reduced.

A composition comprising at least one peptide derived from the C-terminal segment of troponin T, the at least one peptide optionally fused to at least one cardiac-targeting peptide and / or at least one cell-penetrating peptide, polynucleotides and vectors encoding the composition, and methods of using the composition and vector in a method of treating heart failure, e.g., diastolic heart failure.

A system and method are described that provides non-invasive detection and quantification of systolic and diastolic heart failure, including subclinical, asymptomatic systolic and diastolic heart failure. The invention is a novel method for processing physiological data and deriving clinical implications and prognosis. The invention is based on extracting data from simultaneous data streams of electrocardiogram, phonocardiogram, and left ventricular pressure to be graphically displayed in a Wiggers diagram that depicts the entire cardiac cycle.

The present disclosure features compositions and methods for modulating mammalian muscle contraction. The present disclosure also features compositions and methods for the treatment of a cardiac disease or disorder (e.g., a cardiac disorder involving abnormal force production and / or cessation in cardiac muscle, cardiac hypertrophy, reduced systolic function, reduced diastolic function, maladaptive hypertrophy, heart failure with preserved systolic function, diastolic heart failure, systolic heart failure, hypertensive heart disease, aortic and mitral valve disease, pulmonary valve disease, hypertrophic cardiomyopathy, post ischemic and post-infarction cardiac remodeling, or cardiac failure) in a subject. The methods involve administering flightin polypeptides and / or WYR polypeptides, or polynucleotides encoding the same, as described herein.